Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Profit After Tax (2016 - 2026)

Viridian Therapeutics, Inc.\DE has reported Profit After Tax over the past 12 years, most recently at -$120.4 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$120.4 million for Q4 2025, down 50.96% from a year ago — trailing twelve months through Dec 2025 was -$342.6 million (down 26.91% YoY), and the annual figure for FY2025 was -$342.6 million, down 26.91%.
  • Profit After Tax for Q4 2025 was -$120.4 million at Viridian Therapeutics, Inc.\DE, down from -$34.6 million in the prior quarter.
  • Over the last five years, Profit After Tax for VRDN hit a ceiling of -$14.0 million in Q3 2021 and a floor of -$120.4 million in Q4 2025.
  • Median Profit After Tax over the past 5 years was -$48.1 million (2023), compared with a mean of -$53.0 million.
  • Peak annual rise in Profit After Tax hit 68.1% in 2021, while the deepest fall reached 179.16% in 2021.
  • Viridian Therapeutics, Inc.\DE's Profit After Tax stood at -$28.9 million in 2021, then crashed by 58.17% to -$45.8 million in 2022, then crashed by 46.03% to -$66.9 million in 2023, then dropped by 19.24% to -$79.7 million in 2024, then tumbled by 50.96% to -$120.4 million in 2025.
  • The last three reported values for Profit After Tax were -$120.4 million (Q4 2025), -$34.6 million (Q3 2025), and -$100.7 million (Q2 2025) per Business Quant data.